Myelodysplastic Syndromes (MDS)
Catherine Chittick, RN, BSN
Jenna Moran, MSN, FNP-BC
Aura Ramos, RN, BSN
Tamibarotene
SY-1425
Germline mutations in MDS/AML predisposition disorders
Purpose of review: Recognition of hereditary hematopoietic malignancies impacts patient management as well as health surveillance strategies for the patient and relatives who share the causative DNA variant. In this review, barriers to the diagnosis and management of patients are outlined.
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management"
Disease overview: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation.
Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors
We compared outcomes in 603 patients with myelodysplastic syndrome (MDS) after HLA HLA: See human leukocyte antigen. -haploidentical relative (n = 176) and HLA-matched unrelated (n = 427) donor hematopoietic cell transplan
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
Hypomethylating agents (HMAs) are widely used in the treatment of myelodysplastic syndromes myelodysplastic syndromes: (my-eh
